MARKET

CTIC

CTIC

CTi Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.430
-0.020
-0.82%
Opening 12:06 06/16 EDT
OPEN
2.440
PREV CLOSE
2.450
HIGH
2.470
LOW
2.410
VOLUME
187.04K
TURNOVER
--
52 WEEK HIGH
4.130
52 WEEK LOW
0.9629
MARKET CAP
226.68M
P/E (TTM)
-3.1567
1D
5D
1M
3M
1Y
5Y
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity In...
PR Newswire - PRF · 6d ago
CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Wednesday, June 16
/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at . The conference will be held in a virtual meeting format.
PR Newswire - PRF · 06/09 11:00
BRIEF-CTI BioPharma Q1 Loss Per Share $0.23
reuters.com · 06/01 20:26
CTI BioPharma EPS misses by $0.02
CTI BioPharma (CTIC): Q1 GAAP EPS of -$0.23 misses by $0.02.Operating loss was $17.1M vs. $119.9M last year same quarter.As of March 31, 2021, cash, cash equivalents and short-term investments
Seekingalpha · 06/01 20:15
CTI BioPharma Widens Q1 Loss from Year Ago
MT Newswires · 06/01 17:13
CTI BioPharma Shares Shoot Higher as FDA Accepts Pacritinib Review Application In Bone Marrow Cancer
Benzinga · 06/01 13:33
Thinking about buying stock in Vertex Energy, CTI BioPharma, Peabody Energy, Express, or US Well Services?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTNR, CTIC, BTU, EXPR, and USWS.
PR Newswire - PRF · 06/01 13:31
FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA
CTI BioPharma (CTIC) shares up more than 5% premarket after announcing that the U.S. FDA has accepted its New Drug Application ((NDA)) for pacritinib as a treatment for myelofibrosis patients with severe
Seekingalpha · 06/01 12:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTIC. Analyze the recent business situations of CTi Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTIC stock price target is 7.34 with a high estimate of 15.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 91
Institutional Holdings: 44.35M
% Owned: 47.55%
Shares Outstanding: 93.28M
TypeInstitutionsShares
Increased
22
3.97M
New
6
308.12K
Decreased
11
3.66M
Sold Out
13
941.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.13%
Pharmaceuticals & Medical Research
+0.16%
Key Executives
Chairman/Director
Laurent Fischer
President/Chief Executive Officer/Director
Adam Craig
Chief Financial Officer/Executive Vice President
David Kirske
Chief Operating Officer
Bruce Seeley
Executive Vice President/Chief Scientific Officer
Jack Singer
Senior Vice President
Nancy Boman
Senior Vice President
Monique Greer
Director
Michael Metzger
Director
Matthew Perry
Independent Director
David Parkinson
Independent Director
Frederick Telling
Independent Director
Reed Tuckson
No Data
About CTIC
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Webull offers kinds of CTI BioPharma Corp stock information, including NASDAQ:CTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTIC stock methods without spending real money on the virtual paper trading platform.